Trial of Rituximab Given Pre-Transplant to Sensitised Live Donor Kidney Recipients
Status:
Unknown status
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
About one third of prospective kidney transplant recipients have antibodies in their blood
directed against the tissues of their only available kidney donor. Recently,
"desensitisation" treatments when administered pre-transplant have allowed successful
transplantation of these patients despite high rates of acute antibody mediated rejection
(AAMR). The investigators propose to test in a randomised controlled trial whether rituximab,
a monoclonal antibody that depletes B-lymphocytes, will safely lower antibody mediated
rejection (AMR) rates when added to "standard" therapy. The investigators will also test
whether rituximab enables more patients to achieve a negative crossmatch against their donor
and thereby allow more transplants to proceed.
Phase:
Phase 2
Details
Lead Sponsor:
Hunter and New England Health
Collaborators:
Auckland City Hospital Melbourne Health Monash Medical Centre Princess Alexandra Hospital, Brisbane, Australia Royal Adelaide Hospital Royal Perth Hospital Royal Prince Alfred Hospital, Sydney, Australia Westmead Hospital